Updated:
AVICELLA CAPITAL, LLC
Avicella Capital, LLC is a Delaware-based venture capital firm that finds and invests in early-stage healthcare assets across therapeutics, devices,...
AVICELLA CAPITAL, LLC
Avicella Capital, LLC is a Delaware-based venture capital firm that finds and invests in early-stage healthcare assets across therapeutics, devices, diagnostics, and health tech. The firm's fundamental purpose is to improve patient outcomes, increase healthcare quality, and prolong human longevity by backing cutting-edge medical technologies and therapies. Within therapeutics, Avicella seeks assets and devices with established proof-of-concept and an established or dissected mechanism of action, regardless of molecule size or medical indication. Its devices focus targets modern medical devices that enable quicker recovery, reduced pain, and personalized, data-driven healthcare decisions. In diagnostics, the firm looks for advanced technologies that enhance diagnosis and treatment precision through early disease detection and targeted interventions, while its health tech focus targets companies leveraging real-time data, sophisticated AI, and workflow optimization. Avicella has made three investments, including a Series B investment in Faeth Therapeutics on October 20, 2025. Portfolio companies listed on the firm's website include Chiara, Convergence, Faeth Therapeutics, Kinoxis, Eilean Therapeutics, Mondego Bio, and Upyther.
General information
Firm type
Venture Capital
Location
Country
United States
Corporate office
United States
Sector focus
Frequently asked questions
What is Avicella Capital's investment focus?
Avicella Capital invests in early-stage healthcare assets across four sectors: therapeutics, devices, diagnostics, and health tech, targeting assets with established proof-of-concept that improve patient outcomes, increase healthcare quality, and prolong human longevity.
What are Avicella Capital's criteria for therapeutic assets?
The firm seeks therapeutic assets and devices with established proof-of-concept and an established or dissected mechanism of action, regardless of the size of molecule or medical indication.
What notable investment has Avicella Capital made?
Avicella Capital has made three investments, including a Series B investment in Faeth Therapeutics on October 20, 2025.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: